STCube Inc (052020) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of STCube Inc stock KRW 3,994, price KRW 6,070, that is 34.2% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
STCube Inc
052020 · KQExpensive (fair value 34% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range 3,882 KRW – 23,439 KRW · fair‑value band 2,996 KRW – 4,992 KRW · the 6,070 KRW price screens above the 3,994 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether STCube is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea.
Show moreShow less
Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a technology designed to screen for antibodies that selectively mask specific sites of target proteins; and Glyco-Specific Antibody Characterization and Optimization Platform, a technology designed to optimize characteristics exerted by antibodies that mask specific sites of target proteins.
The company's product pipeline consists of various anti-cancer drugs, including programmed death ligand 1, a type of protein, which is expressed in cancer cells and interferes with the natural tumor killing of immune cells; programmed death-1, a type of protein that is expressed in T cells; and cytotoxic T-lymphocyte associated protein 4, a protein that inhibits the activity of T-cells that can kill cancer cells.
Its product pipeline also comprises lymphocyte-activation gene 3, a type of protein, which exists in the cell membrane of immune cells, such as T-cells and NK cells. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008.
STCube, Inc. was founded in 1989 and is headquartered in Seoul, South Korea.
Stock analysis
STCube Inc (052020) currently trades at 6,070 KRW, while our estimate is 3,994 KRW, 34% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 2,996 KRW (bear) to 4,992 KRW (bull), the price of 6,070 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Technology sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
STCube Inc reported revenue of 7.0B KRW in FY2025 versus 7.9B KRW in FY2021, a compound −3.1%/yr. Reported net income was −21.8B KRW in FY2025.
Key figures
Market cap 412B KRW (≈ $308M) Small · P/S ratio 68.9 · Return on equity −3,493% · Return on assets (EBIT) −41.3% (5-year average) · Operating margin −331% · Revenue (TTM) 6.5B KRW · Revenue growth (YoY) −31.3% · Free cash flow −20.7B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (medium confidence).
What moves the price
The share trades about 73% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −4% fair-value upside, at −34%, 052020 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
052020 screens overvalued: fair value 34% below the price. Compare with VINATech Co →
Compare STCube Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Electronic Equipment & Parts · 21 stocks
Valuation Multiplesvs Electronic Equipment & Parts median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Electronic Equipment & Parts stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Partron Co 091700 | 3,790 KRW | 10,012 KRW | +164% | vs 052020 |
| Namuga Co 190510 | 18,850 KRW | 36,136 KRW | +92% | vs 052020 |
| Powerlogics. Co 047310 | 2,615 KRW | 5,000 KRW | +91% | vs 052020 |
| MNTech Co 095500 | 5,450 KRW | 7,368 KRW | +35% | vs 052020 |
| KHVATEC Co 060720 | 10,050 KRW | 9,609 KRW | −4% | vs 052020 |
| e-LITECOM CO., Ltd 041520 | 10,650 KRW | 8,748 KRW | −18% | vs 052020 |
| Amotech Co 052710 | 12,930 KRW | 9,474 KRW | −27% | vs 052020 |
| Yujin Robot Co 056080 | 8,250 KRW | 5,015 KRW | −39% | vs 052020 |
| Ajinextek Co 059120 | 5,550 KRW | 1,260 KRW | −77% | vs 052020 |
| VINATech Co 126340 | 82,000 KRW | 18,536 KRW | −77% | vs 052020 |
Explore undervalued stocks
More undervalued Technology stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is STCube Inc (052020) overvalued or undervalued?
What is the fair value of 052020?
What is the quality score of 052020?
What is the price target for STCube Inc (052020)?
What is the STCube Inc stock forecast for 2026?
What is the revenue of STCube Inc (052020)?
What is the intrinsic value of STCube Inc (052020)?
Is STCube Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 052020?
How much is STCube Inc worth?
What do the bullish and bearish scenarios say about 052020?
How far is 052020 from its 52-week high?
Which stocks are comparable to STCube Inc?
Is STCube Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of STCube Inc (052020)?
What should I pay attention to with STCube Inc right now?
Key figures of STCube Inc
How large is the market capitalisation of STCube Inc (052020)?
What is the P/S ratio of STCube Inc (052020)?
What is the return on equity of STCube Inc (052020)?
What is the EBIT return on assets of STCube Inc (052020)?
What is the operating margin of STCube Inc (052020)?
How fast is revenue growing at STCube Inc (052020)?
How much free cash flow does STCube Inc (052020) generate?
Watch STCube Inc in the live analysis
One click puts STCube Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.